Evaluation of an Ion Chromatography Method for Quantitating Sulfate in Plasma, Serum and Urine

Dawson, Paul A.; McWhinney, Avis; Reimer, Matthew N.; Bowling, Francis

doi:10.4172/2157-7064.1000411

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding suggests that the turbidometric microassay underestimates the sulfate level in plasma and urine by at least 34 %. We found that to be the case when we compared sulfate levels measured with the turbidometric microassay and an ion chromatography method [12] . The turbidometric microassay consistently yielded sulfate levels that were 32 % and 33 % lower in pig plasma ( n = 33) and urine ( n = 5) samples, respectively, when compared to the ion chromatography method.…”

Section: Methods Validationmentioning

confidence: 89%

“…Several methods for measuring sulfate in biological samples have been described, but many of those methods use toxic reagents [11] or require high-cost specialized equipment such as ion chromatography [12] . A relatively low-cost and low-hazard methodology is the turbidometric assay that uses BaCl 2 agarose solution to precipitate sulfate [13] .…”

Section: Introductionmentioning

confidence: 99%

“…In this study, we report a modified turbidometric microassay for measuring sulfate in low sample volumes. In addition, we tested a range of assay parameters, including reagent stability and reagent incubation times, as well as comparison between the turbidometric microassay and a validated ion chromatography method [12] .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Modified turbidometric microassay for the measurement of sulfate in plasma and urine

Vijayakumar,

McWhinney,

Eiby

et al. 2024

MethodsX

View full text Add to dashboard Cite

Section: Methods Validationmentioning

confidence: 89%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Modified turbidometric microassay for the measurement of sulfate in plasma and urine

Vijayakumar,

McWhinney,

Eiby

et al. 2024

MethodsX

View full text Add to dashboard Cite

“…Plasma samples are transported to the lead study site where they are batch-analysed. Plasma sulfate concentrations are measured using ion chromatography with suppressed conductivity detection using a Dionex ICS2000, as previously described 48. Plasma magnesium concentrations are quantitated as per routine testing using a Vitros 5.1 FS chemistry analyser.…”

Section: Methodsmentioning

confidence: 99%

“…The cotton wool ball is thawed and centrifuged to obtain urine for analysis. Urinary and plasma sulfate concentrations are measured as previously described 48. Urinary and plasma creatinine is measured as per routine testing using a Vitros 5.1 FS chemistry analyser.…”

Section: Methodsmentioning

confidence: 99%

SuPreme Study: a protocol to study the neuroprotective potential of sulfate among very/extremely preterm infants

et al. 2023

Self Cite

View full text Add to dashboard Cite

IntroductionAntenatal maternal magnesium sulfate (MgSO4) administration is a proven efficacious neuroprotective treatment reducing the risk of cerebral palsy (CP) among infants born preterm. Identification of the neuroprotective component with target plasma concentrations could lead to neonatal treatment with greater efficacy and accessibility.Methods and analysisThis is a prospective observational cohort study, in three tertiary Australian centres. Participants are preterm infants, irrespective of antenatal MgSO4exposure, born in 2013–2020 at 24+0to 31+6weeks gestation, and followed up to 2 years corrected age (CA) (to September 2023). 1595 participants are required (allowing for 17% deaths/loss to follow-up) to detect a clinically significant reduction (30% relative risk reduction) in CP when sulfate concentration at 7 days of age is 1 SD above the mean.A blood sample is collected on day 7 of age for plasma sulfate and magnesium measurement. In a subset of participants multiple blood and urine samples are collected for pharmacokinetic studies, between days 1–28, and in a further subset mother/infant blood is screened for genetic variants of sulfate transporter genes.The primary outcome is CP. Surviving infants are assessed for high risk of CP at 12–14 weeks CA according to Prechtl’s Method to assess General Movements. Follow-up at 2 years CA includes assessments for CP, cognitive, language and motor development, and social/behavioural difficulties.Multivariate analyses will examine the association between day 7 plasma sulfate/magnesium concentrations with adverse neurodevelopmental outcomes. A population pharmacokinetic model for sulfate in the preterm infant will be created using non-linear mixed-effects modelling.Ethics and disseminationThe study has been approved by Mater Misericordiae Ltd Human Research Ethics Committee (HREC/14/MHS/188). Results will be disseminated in peer-reviewed journal publications, and provided to the funding bodies. Using consumer input, a summary will be prepared for participants and consumer groups.

show abstract

Serum sulfate level and Slc13a1 mRNA expression remain unaltered in a mouse model of moderate vitamin D deficiency

Atcheson

Dawson

2022

Mol Cell Biochem

View full text Add to dashboard Cite

Evaluation of an Ion Chromatography Method for Quantitating Sulfate in Plasma, Serum and Urine

Cited by 4 publications

References 0 publications

Modified turbidometric microassay for the measurement of sulfate in plasma and urine

Modified turbidometric microassay for the measurement of sulfate in plasma and urine

SuPreme Study: a protocol to study the neuroprotective potential of sulfate among very/extremely preterm infants

Serum sulfate level and Slc13a1 mRNA expression remain unaltered in a mouse model of moderate vitamin D deficiency

Contact Info

Product

Resources

About